Project Grant R01CA300773
- Federal Grant Award Summary The National Cancer Institute awarded Yale University a $478,532 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This research initiative will investigate the biological and clinical significance of spatial immune heterogeneity in non-small cell lung cancer (NSCLC), with particular focus on characterizing how the spatial distribution of tumor-infiltrating lymphocytes (TILs) and tertiary...
- Federal Grant Award Summary Yale University received a $100,228 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) to investigate the regulation of membrane-chromatin interactions in mitotic nuclear formation and cancer cell survival. The award, effective December 1, 2026, through August 31, 2029, supports research aimed at understanding how the LEM-domain protein LEMD2 and endoplasmic reticulum (ER) membrane availability cooperate...
- Yale University received a $696,189 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on April 7, 2026, with a completion date of March 31, 2031. The grant supports fundamental research investigating the mechanisms of CD8 T cell differentiation in tumor-draining lymph nodes (TDLNs) in the context of lung adenocarcinoma (LUAD). The research aims to understand why most LUAD patients do not respond to programmed death-1 (PD-1)...
- Federal Project Grant Award Summary Yale University received a $150,104 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective January 16, 2026, through August 31, 2028. The award supports research investigating the impact of aberrant 5-methylcytosine (M5C) mRNA modification on translation initiation and cancer development. The project aims to determine how dose-sensitive M5C modifications in 5' untranslated regions (5'-UTRs) regulate...
- Federal Project Grant Award Summary Yale University received a $130,490 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded June 1, 2026, with a completion date of May 31, 2028. This award supports biomedical training and research career development initiatives focused on understanding the cellular and molecular mechanisms of early-onset colorectal cancer (EOCRC). The project addresses a significant public health concern—while...
- Federal Grant Award Summary Yale University received a $147,486 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded July 1, 2025, with a completion date of June 30, 2028. This research grant funds investigation into the role of glycosylated RNAs (glycoRNAs)—RNA molecules post-transcriptionally modified with sialylated-N glycans—in acute myeloid leukemia (AML). The project delivers scientific research outputs across three primary aims:...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $136,266 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective July 14, 2025, through June 30, 2027. The grant funds research aimed at identifying therapeutic strategies to prevent small cell lung cancer (SCLC) histological transformation in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients. The research focuses on understanding the...
- Federal Project Grant Award Summary Yale University received a $610,637 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026 through March 31, 2031. The award supports bioengineering research focused on developing an optimized drug delivery platform utilizing bioadhesive and non-adhesive biodegradable nanoparticles for locoregional treatment of advanced melanoma. The research will engineer these nanoparticle systems...
- Federal Project Grant Award Summary Yale University received a $192,564 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective September 1, 2025 through August 31, 2028. The award supports the development of innovative dual-target Protease Targeted Chimera (PROTAC)-based protein degraders designed to overcome therapy resistance in metastatic castration-resistant prostate cancer (MCRPC). The research addresses lineage...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...
Yale University received a $577,750 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective June 1, 2026 through May 31, 2031. This research initiative investigates the functional role of the PBAF (polybromo-associated BAF) chromatin remodeling complex in small cell lung cancer (SCLC) development and progression. The project delivers mechanistic research examining how PBAF inactivation alters chromatin structure, transcription factor binding, and gene expression programs that drive SCLC initiation, progression, and metastasis. The funded research encompasses three primary aims: establishing the functional importance of PBAF during SCLC development across multiple disease stages; elucidating transcriptional mechanisms underlying PBAF-deficiency effects; and identifying therapeutic vulnerabilities and drug targets in PBAF-deficient SCLC models. Through genomic analyses, cellular modeling, and transcriptional profiling, this project will translate fundamental mechanistic findings regarding SCLC biology into clinically actionable therapeutic strategies. The research is performed at Yale University's New Haven, Connecticut location and addresses the urgent clinical need for more effective SCLC therapies by characterizing epigenetic and transcriptional mechanisms that promote this highly aggressive neuroendocrine carcinoma.Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $577.8k | 6/3/26 |